Alembic Pharmaceuticals Limited has achieved a significant milestone with the US Food & Drug Administration’s (USFDA) final approval of its Abbreviated New Drug Application (ANDA) for Icatibant Injection, used in the treatment of acute attacks of hereditary angioedema (HAE) in adults. This approval marks the first peptide product approval for Alembic, showcasing their commitment to […]
In a pivotal move bolstering its footprint in the global pharmaceutical landscape, Aurobindo Pharma Limited’s subsidiary, Eugia Pharma Specialities Limited, has achieved final authorization from the US Food & Drug Administration (FDA) to produce and commercialize their Icatibant Injection, 30 mg/3 mL. This development comes as a significant milestone as the injection stands as a […]
